These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 16121404)
1. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Zhou Z; Guan H; Duan X; Kleinerman ES Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404 [TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909 [TBL] [Abstract][Full Text] [Related]
3. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481 [TBL] [Abstract][Full Text] [Related]
4. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121 [TBL] [Abstract][Full Text] [Related]
6. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794 [TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477 [TBL] [Abstract][Full Text] [Related]
8. Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. Tanaka H; Tanabe N; Shoji M; Suzuki N; Katono T; Sato S; Motohashi M; Maeno M Life Sci; 2006 Mar; 78(15):1733-40. PubMed ID: 16266722 [TBL] [Abstract][Full Text] [Related]
9. Tissue-Engineered Model of Human Osteolytic Bone Tumor. Villasante A; Marturano-Kruik A; Robinson ST; Liu Z; Guo XE; Vunjak-Novakovic G Tissue Eng Part C Methods; 2017 Feb; 23(2):98-107. PubMed ID: 28068876 [TBL] [Abstract][Full Text] [Related]
10. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446 [TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486 [TBL] [Abstract][Full Text] [Related]
12. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692 [TBL] [Abstract][Full Text] [Related]
14. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653 [TBL] [Abstract][Full Text] [Related]
16. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217 [TBL] [Abstract][Full Text] [Related]
17. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526 [TBL] [Abstract][Full Text] [Related]
18. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433 [TBL] [Abstract][Full Text] [Related]
20. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. Yamada T; Muguruma H; Yano S; Ikuta K; Ogino H; Kakiuchi S; Hanibuchi M; Uehara H; Nishioka Y; Sone S Mol Cancer Ther; 2009 Jan; 8(1):119-26. PubMed ID: 19139120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]